Clinical Overview
Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the evening or with dinner with water. Taking with food enhances fenofibrate absorption. Follow a low-fat, cholesterol-lowering diet.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyspepsia, nausea, abdominal pain, headache, mild transaminitis, muscle aches. Rare/Severe: Severe rhabdomyolysis with acute kidney injury, severe drug-induced liver injury, cholelithiasis (gallstones), and pancreatitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Increased risk of serious myopathy and rhabdomyolysis when statins are combined with fibrates; instruct patients to report unexplained muscle pain, tenderness, or weakness immediately. Contraindicated in active liver disease, gallbladder disease, severe renal impairment, and pregnancy/lactation. Monitor baseline and periodic LFTs and CPK.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Rosuvastatin Tablets 40mg
HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).
S-Adenosyl L-Methionine 200mg Tablets
S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.
S-Adenosyl L- Methionine 400mg Tablets
S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.